These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 11422206

  • 21. Immunopathogenesis of inflammatory myopathies.
    Dalakas MC.
    Ann Neurol; 1995 May; 37 Suppl 1():S74-86. PubMed ID: 8968219
    [Abstract] [Full Text] [Related]

  • 22. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis.
    Sugihara T, Sekine C, Nakae T, Kohyama K, Harigai M, Iwakura Y, Matsumoto Y, Miyasaka N, Kohsaka H.
    Arthritis Rheum; 2007 Apr; 56(4):1304-14. PubMed ID: 17394136
    [Abstract] [Full Text] [Related]

  • 23. Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins.
    Appeltshauser L, Weishaupt A, Sommer C, Doppler K.
    Exp Neurol; 2017 Jan; 287(Pt 1):84-90. PubMed ID: 27746185
    [Abstract] [Full Text] [Related]

  • 24. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg").
    Stangel M, Compston A, Scolding NJ.
    J Neuroimmunol; 2000 Mar 01; 103(2):195-201. PubMed ID: 10696915
    [Abstract] [Full Text] [Related]

  • 25. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
    Dalakas MC.
    Clin Rev Allergy Immunol; 2005 Dec 01; 29(3):255-69. PubMed ID: 16391401
    [Abstract] [Full Text] [Related]

  • 26. High-dose intravenous immunoglobulin treatment activates complement in vivo.
    Mollnes TE, Høgåsen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R.
    Scand J Immunol; 1998 Sep 01; 48(3):312-7. PubMed ID: 9743219
    [Abstract] [Full Text] [Related]

  • 27. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.
    Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, Jelezarova E, Späth PJ.
    Blood; 2004 Jan 15; 103(2):465-72. PubMed ID: 14512320
    [Abstract] [Full Text] [Related]

  • 28. Adhesion molecule expression in experimental myositis.
    Ito T, Kumamoto T, Horinouchi H, Yukishige K, Sugihara R, Fujimoto S, Tsuda T.
    Muscle Nerve; 2002 Mar 15; 25(3):409-18. PubMed ID: 11870719
    [Abstract] [Full Text] [Related]

  • 29. C-protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats.
    Kohyama K, Matsumoto Y.
    J Neuroimmunol; 1999 Aug 03; 98(2):130-5. PubMed ID: 10430046
    [Abstract] [Full Text] [Related]

  • 30. Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.
    Quast I, Keller CW, Weber P, Schneider C, von Gunten S, Lünemann JD.
    J Neuroinflammation; 2016 Feb 18; 13():42. PubMed ID: 26893156
    [Abstract] [Full Text] [Related]

  • 31. From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.
    Patel SY, Kumararatne DS.
    Clin Exp Immunol; 2001 May 18; 124(2):169-71. PubMed ID: 11422191
    [No Abstract] [Full Text] [Related]

  • 32. Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury.
    Dantas M, Costa RS, Barbosa JE, Graeff MS, Sarti W, De Carvalho IF.
    Clin Exp Immunol; 2000 Jul 18; 121(1):139-45. PubMed ID: 10886251
    [Abstract] [Full Text] [Related]

  • 33. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance.
    Basta M, Langlois PF, Marques M, Frank MM, Fries LF.
    Blood; 1989 Jul 18; 74(1):326-33. PubMed ID: 2752117
    [Abstract] [Full Text] [Related]

  • 34. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
    Wagner E, Platt JL, Frank MM.
    J Immunol; 1998 Feb 15; 160(4):1936-43. PubMed ID: 9469456
    [Abstract] [Full Text] [Related]

  • 35. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy.
    Yuki N, Watanabe H, Nakajima T, Späth PJ.
    J Neurol Neurosurg Psychiatry; 2011 Jan 15; 82(1):87-91. PubMed ID: 20667861
    [Abstract] [Full Text] [Related]

  • 36. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway.
    Basta M, Fries LF, Frank MM.
    Blood; 1991 Aug 01; 78(3):700-2. PubMed ID: 1859883
    [Abstract] [Full Text] [Related]

  • 37. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I.
    J Neurol; 2005 May 01; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [Abstract] [Full Text] [Related]

  • 38. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
    Dalakas MC.
    JAMA; 2004 May 19; 291(19):2367-75. PubMed ID: 15150209
    [Abstract] [Full Text] [Related]

  • 39. Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition.
    Sudo M, Yamaguchi Y, Späth PJ, Matsumoto-Morita K, Ong BK, Shahrizaila N, Yuki N.
    PLoS One; 2014 May 19; 9(9):e107772. PubMed ID: 25259950
    [Abstract] [Full Text] [Related]

  • 40. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
    Dalakas MC.
    Neurology; 1998 Dec 19; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.